Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016
Published Jun 15, 2016
62 pages — Published Jun 15, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016, provides in depth analysis on Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted pipeline therapeutics.

The report provides comprehensive information on the Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)
- The report reviews Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)
- Identify the use of drugs for target identification and drug repurposing

  
Source:
Document ID
GMDHC0058TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Overview81
Therapeutics Development93
  Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Products under Development by Stage of Development91
  Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Products under Development by Therapy Area101
  Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Products under Development by Indication111
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Pipeline Products Glance123
  Late Stage Products121
  Early Stage Products131
  Unknown Stage Products141
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Products under Development by Companies152
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Products under Development by Universities/Institutes172
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Therapeutics Assessment197
  Assessment by Monotherapy/Combination Products191
  Assessment by Mechanism of Action202
  Assessment by Route of Administration222
  Assessment by Molecule Type242
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Companies Involved in Therapeutics Development2614
  Aduro BioTech, Inc.261
  Agenus, Inc.271
  Alligator Bioscience AB281
  AlphaMab Co., Ltd291
  CytomX Therapeutics, Inc.301
  Hanmi Pharmaceuticals, Co. Ltd.311
  JHL Biotech, Inc.321
  Lytix Biopharma AS331
  Novartis AG341
  OncoImmune, Inc.351
  Pfizer Inc.361
  Premier Biomedical Inc.371
  PsiOxus Therapeutics Limited381
  Sutro Biopharma, Inc.391
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Drug Profiles4019
  ADC-1015 Drug Profile401
  AGEN-2041 Drug Profile411
  Anti-CTLA4 + LTX-315 Drug Profile421
  Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor Drug Profile431
  Biologic to Antagonize CTLA4 for Solid Tumor Drug Profile441
  Biologics to Target CTLA4 and TNF Alpha Drug Profile451
  JMW-3B3 Drug Profile461
  KN-044 Drug Profile471
  Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology Drug Profile481
  Monoclonal Antibody Conjugate to Target CTLA-4 for Oncology Drug Profile491
  Monoclonal Antibody to Antagonize CTLA-4 for Oncology Drug Profile501
  Monoclonal Antibody to Antagonize CTLA4 for Breast Cancer Drug Profile511
  Monoclonal Antibody to Antagonize CTLA4 for Oncology Drug Profile521
  Monoclonal Antibody to Antagonize CTLA4 for Oncology Drug Profile531
  Monoclonal Antibody to Target GLUT2 and CTLA4 for Type 1 Diabetes Drug Profile541
  Monocloncal Antibody to Inhibit CTLA-4 for Oncology Drug Profile551
  ONC-392 Drug Profile561
  Oncolytic Viruses to Antagonize CTLA4 for Solid Tumors Drug Profile571
  Small Molecule to Target CTLA4 and IFNGR for RRMS Drug Profile581
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Dormant Projects591
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Featured News &Press Releases601
  Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate AGEN2041 at the American Association for Cancer Research (AACR) 2016 Annual Meeting601
Appendix612
  Methodology611
  Coverage611
  Secondary Research611
  Primary Research611
  Expert Panel Validation611
  Contact Us611
  Disclaimer621

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cytotoxic-T-Lymphocyte-Protein-4-CTLA-4-or-CD152-Pipeline-Review-H1-2016-2088-15963>
  
APA:
Global Markets Direct - Market Research. (2016). Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cytotoxic-T-Lymphocyte-Protein-4-CTLA-4-or-CD152-Pipeline-Review-H1-2016-2088-15963>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.